Amivantamab with chemotherapy - Non-small cell lung cancer with EGFR exon 20 insertions

被引：0
|
作者：
Drappier, Noemie [1 ]
Pierret, Thomas [2 ]
机构：
[1] Univ Montpellier, Fac Med, F-34090 Montpellier, France
[2] Hosp Civils Lyon, Hop Louis Pradel, Serv Hosp Univ Pneumol, F-69500 Bron, France
来源：
BULLETIN DU CANCER | 2024年 / 111卷 / 12期
关键词：
Non-small cell lung cancer; EGFR exon 20 insertions; Amivantamab; Chemotherapy;
D O I：
10.1016/j.bulcan.2024.08.014
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1085 / 1087
页数：3
相关论文
共 50 条
  • [21] Effectiveness and safety of amivantamab in EGFR exon 20 insertion (E20I) mutations in non-small cell lung cancer (NSCLC)
    Choi, Dae-Ho
    Jung, Hyun Ae
    Park, Sehhoon
    Sun, Jong -Mu
    Ahn, Jin Seok
    Ahn, Myung-Ju
    Lee, Se-Hoon
    TRANSLATIONAL LUNG CANCER RESEARCH, 2023, 12 (12) : 2448 - 2459
  • [22] Amivantamab and Mobocertinib in Exon 20 insertions EGFR Mutant Lung Cancer, Challenge To The Current Guidelines
    Olivier, Timothee
    Prasad, Vinay
    TRANSLATIONAL ONCOLOGY, 2022, 23
  • [23] Bispecific Approach for Patients with non-small cell Lung Cancer Benefiting from Amivantamab for EGFR-Exon-20-Insertion Mutations
    Rudesheim, Sabine M.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 (04) : 214 - 214
  • [24] Matching-adjusted indirect comparison (MAIC) of mobocertinib versus amivantamab in patients with non-small cell lung cancer (NSCLC) with EGFR exon 20 insertions (ex20ins).
    Ou, Sai-Hong Ignatius
    Prawitz, Thibaud
    Lin, Huamao Mark
    Hong, Jin-Liern
    Tan, Minal
    Proskorovsky, Irina
    Hernandez, Luis
    Jin, Shu
    Zhang, Pingkuan
    Lin, Jianchang
    Patel, Jyoti D.
    Nguyen, Danny
    Neal, Joel W.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [25] Clinical Features, Outcomes, and Biology of EGFR exon 20 Insertions in a Cohort of Hispanic Patients with Non-small Cell Lung Cancer
    Motta, R.
    Cardona, A.
    Cruz, G.
    Aliaga, C.
    Carracedo, C.
    Raez, L.
    Arrieta, O.
    Mezquita, L.
    Albarran, V.
    Corrales, L.
    Bacon, L.
    Rojas, L.
    Zuluaga, J.
    Martin, C.
    Dabalsa, A.
    Ruiz-Patino, A.
    Freitas, H.
    Cordeiro, V.
    Failoc-Rojas, V.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S666 - S666
  • [26] Cost-effectiveness analysis of amivantamab plus chemotherapy for non-small cell lung cancer patients with epidermal growth factor receptor exon 20 insertions in the United States
    Cao, Yingdan
    Yi, Hongbin
    Shi, Fenghao
    Wei, Xiaoxia
    Han, Sheng
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2024, : 1335 - 1344
  • [27] Targeting EGFR exon 20 insertion mutations in non-small cell lung cancer
    Simon Vyse
    Paul H. Huang
    Signal Transduction and Targeted Therapy, 4
  • [28] Targeting EGFR exon 20 insertion mutations in non-small cell lung cancer
    Vyse, Simon
    Huang, Paul H.
    SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2019, 4 (1)
  • [29] Amivantamab is effective in NSCLC harbouring EGFR exon 20 insertions
    Romero, Diana
    NATURE REVIEWS CLINICAL ONCOLOGY, 2021, 18 (10) : 604 - 604
  • [30] Amivantamab is effective in NSCLC harbouring EGFR exon 20 insertions
    Diana Romero
    Nature Reviews Clinical Oncology, 2021, 18 : 604 - 604
12345